Latest News-GC Corp. Mediaroom_Page

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biophar...

2023-08-25 15:14 2044

Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.

* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. Y...

2023-08-18 08:58 2611

U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceut...

2023-07-31 13:20 1970

GC Genome enables the prognosis prediction and targeted treatment in breast cancer patients

YONGIN, South Korea, July 26, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnos...

2023-07-27 08:53 1446

GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent

* Striving to further expand its territory to Africa and the Middle East from Southeast Asia and ...

2023-07-21 16:47 2345

GC Genome's New Study Reveals Link Between Gut Microbiome and High Blood Pressure

- A large Korean population study provides scientific evidence that altering the gut microbiome com...

2023-06-15 08:32 1823

GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia

* In recognition of securing high-caliber technology in manufacturing plasma derivatives and a tr...

2023-06-02 08:35 2629

GC Genome to Present the Brand New Liquid Biopsy Platform for Cancer Detection at AACR Annual Meeting 2023

YONGIN, South Korea, April 18, 2023 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics co...

2023-04-18 13:36 1896

GC Biopharma celebrates 'World Hemophilia Day'

* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /...

2023-04-18 09:03 1992

GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications

YONGIN, South Korea, April 11, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagno...

2023-04-12 11:06 1952

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors

YONGIN, South Korea, April 9, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnos...

2023-04-10 11:39 1818

Latest News

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.

U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

GC Genome enables the prognosis prediction and targeted treatment in breast cancer patients

GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent

GC Genome's New Study Reveals Link Between Gut Microbiome and High Blood Pressure

GC Biopharma receives a business license for the construction of a plasma fractionation plant and technology transfer in Indonesia

GC Genome to Present the Brand New Liquid Biopsy Platform for Cancer Detection at AACR Annual Meeting 2023

GC Biopharma celebrates 'World Hemophilia Day'

GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors

GC Cell Obtains Anti-bribery Management System Certification

GC Cell and New Management Embarking on a New Chapter

GCCL Develops PBMC Resource Management System

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

GC Biopharma Receives WHO Pre-Qualification for BARYCELA

GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea

GC Labs becomes the first Korean laboratory to obtain certification of CDC standardization programs (VDSCP & HoSt)

GC Biopharma and Speragen Sponsored an Externally Led - Patient Focused Drug Development with FDA Attendance